PRESS RELEASESGD Pharma’s latest annual sustainability report details global environmental,social and ethical efforts
Paris La Défense, FRANCE – 26 June 2023: Global market leader in molded glass packaging
solutions for the pharmaceutical industry, SGD Pharma, has published its latest Corporate
Social Responsibility (CSR) Report 2022 to underscore its company-wide commitment to agreen and sustainable present and future. The 2022 Report is published soon after thecompany received its coveted ECOVADIS Gold award, achieving its highest ever score of 75
out of 100 - the company is currently rated in the top 2% of global companies in the‘Manufacture of glass and glass products’ category.
Key achievements include:
•••••

•

100% of all SGD Pharma owned glass manufacturing plants are ISO 45001
certified
100% of SGD Pharma sites are certified with ISO 14001
100% of critical suppliers have CSR clauses in their contracts
99.5% of our internal cullet is reused in our production process>20% reduction in water consumption vs 2020

86% EHS Maturity Matrix

The company-wide focus on CSR under new CEO Olivier Rousseau and with new investors
PAI Partners on board means stretch targets have been set ahead:•••••

Halve Scope 1 and Scope 2 emissions by 2030
35% reduction in carbon footprint by 2030
65% reduction in carbon footprint by 2040 (compared with 2020 baseline)
Goal: Zero accidents
Reduction of 65% of absolute CO2 emissions by 2024, (consisting of-52%
decrease in CO2 emissions / melted tons and Zero net CO2 emissions)

As a global leader in heavy manufacturing of pharmaceutical-grade glass, SGD Pharma takes
its global and local responsibilities seriously. Each location has an energized CSR plan
deployed locally, and conforms to the company’s overall standards.
The company has made significant BAT (best available technology) investment in its global
plants and infrastructure as part of a continual search for improvements in energy
consumption. This includes furnaces renovations and updated glass production facilities in all
5 plants, including furnace 2 in Sucy-en-Brie, France (leading to a reduction of more than 10%
in C02 and Nox emissions) and Saint-Quentin-La-Motte, France, which has both a full electrical
furnace and a second oxy-fuel combustion furnace equipped with electrical boosting, both ofwhich allow the plant to produce glass with low carbon emissions. SGD Pharma has also
committed to uplift its decarbonization investment by 20% over the coming 15 years.
CSR Spotlight: SGD Pharma Zhanjiang China – planting mangroves
As well as being SA 8000 certified, the SGD Pharma China plant in Zhanjiang supports thelocal community with its local footprint, relationships with local government and with local

PRESS RELEASE
institutions, local hiring policies and by helping to protect biodiversity in Zhanjiang. The city ishome to one of the world’s most successful examples of wetland ecological restoration andSDG Pharma has committed to supporting the community’s efforts to tackle deforestation byplanting mangrove trees. By the end of 2022, SGD Pharma planted a total of 1000 mangroves
trees on the coast of Zhanjiang, China, in association with Zhanjiang Nature and Resource
Bureau.
During a visit to the SGD Pharma Zhanjiang site in April 2023, Zhanjiang Mayor Mr. Zeng Jinze(曾进泽) and a delegation joined CEO Olivier Rousseau, COO Christophe Muguet, and thelocal team at SGD Pharma China, to plant new mangrove roots. The Mayor stressed theimportance of mangrove preservation for Zhanjiang and the many benefits it brings to society
in terms of biodiversity, carbon sync and protection of the coast. SGD Pharma is proud tocontribute to biodiversity and hopes to continue its biodiversity projects in China and otherplants during 2023. A further 300 trees have been planted.
For more information on SGD Pharma’s sustainable actions and to read the 2022 report visit:https://www.sgd-pharma.com/sustainability-0ENDS

About SGD Pharma
SGD Pharma is a global producer of molded and tubular glass for pharmaceutical primary
packaging. Building on over a century of expertise, we provide exceptional quality packaging
solutions dedicated to parenteral, oral, and nasal products for every therapeutic application.
Our worldwide clients are supported by more than 90 agents and distributors and benefit fromongoing innovation at our five best-in-class ISO 15378 certified, GMP compliant manufacturing
plants, giving a truly global supply chain infrastructure.

Marketing & Communication SGD Pharma
Jean-Pascal Marquié – jean-pascal.marquie@sgdgroup.com
The Scott PartnershipAlisha Mountford– sgdpharma@scottpr.com